Independent 5-year pharmaceutical and healthcare industry forecasts for Ukraine.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Ukrainian pharmaceutical and healthcare industry.
Competitive intelligence, Ukrainian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Ukrainian market.
The Ukraine Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to 2011 covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Ukraine Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Ukrainian pharmaceutical and healthcare industry.
Key Benefits of Report
Benchmark It’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Ukraine to test other views – a key input for successful budgeting and strategic business planning in the Ukrainian pharmaceutical and healthcare market.
Target Business Opportunities & Risks in the Ukrainian Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Ukraine.
Exploit The Latest Competitive Ukrainian Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Ukraine.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect It’s forecast analysis, and taken together with It’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
5-Year Industry Forecast
5-Year Forecasts to end-2011 for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism;
OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
Generics market (US$bn)/ as % of total market
Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke It economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
5-Year Macroeconomic Forecasts
It forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. It profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
Executive Summary
The Sector At A Glance
Key Insights On The Pharmaceutical Sector Of the Ukraine
Ukraine’s pharmaceutical market continues to grow rapidly in value terms. Estimates by Russian market research agency RMBC indicate that Ukraine’s packaged pharmaceutical market grew 18% year-on-year (y-o-y) over the first nine months of 2006. It predicts that the Ukrainian market will reach a total retail value of US$1.94bn in 2006, growing to US$2.49bn by 2010. The compound annual growth rate for the market is forecasted at 9.4% for the period 2005 to 2010, making Ukraine one of the fastest growing markets in Central and Eastern Europe. Still, strong recent growth has failed to attract much direct investment in the production sector as multinationals have preferred to invest in production in the larger and comparatively more stable Russian market to the east.
Despite impressive market growth, the year 2006 also served to justify the hesitation of investors in the pharmaceutical and broader healthcare sector in Ukraine. The country’s government was essentially paralysed from mid-2005 to mid-2006, with President Viktor Yushchenko unable to force through a working government until August. With a cabinet headed by Yushchenko’s former arch rival and Party of Regions chief Viktor Yanukovich, the government seemed to creep back to life for much of Q406, only to descend again into conflict in December.
The result of this instability has been reflected in the pharmaceutical market, where a number of decrees have been promulgated and plans announced only for deadlines to slip and implementation postponed. One major example is a decree published by the previous caretaker government at the beginning of 2006 that called for a ‘Plan of Development’
Large scale foreign investment is still notable by its almost complete absence, however, notwithstanding relatively small investments by companies such as Bioton (Poland) in insulin maker Indar and a packaging plant built by Gedeon Richter (Hungary). Rather, strong market players are leading the consolidation process in the domestic market with Darnitsa, Arterium and Borshchagovsky topping the domestic sector. Foreign players will likely stay on the sidelines, waiting to see if Ukraine’s economy continues to defy the odds and grow steadily despite the prospect of further large price hikes on gas imposed by Russia. Ukraine’s mixed picture translates into a continued 10th place rating among the 14 CEE major pharmaceutical markets featured in the Q406 Business Environment Rankings. Without some clear direction by government aimed at simplifying and speeding procedures and dealing with corruption and counterfeiting, the country will remain a secondary market in many ways. Such robust action by the government is, however, unlikely in the foreseeable future.
For more information, Please visit :
http://www.bharatbook.com/
